Growth Financing Positron has recently secured capital with multiple funding rounds totaling at least $12M, including an $8M funding infusion to accelerate growth and market expansion, signaling urgency and capacity for sales initiatives that scale production, install base expansion, and service contracts.

Expanded Product Line The upcoming Affinity PET-CT 4D system and recent NeuSight PET-CT launches indicate a broadened product portfolio across cardiac and oncology imaging, creating cross-sell opportunities to existing nuclear medicine customers and new market segments seeking advanced molecular imaging capabilities.

Strategic Partnerships Collaboration with Shenyang Intelligent Neuclear Technology Co (Neusoft Medical Systems subsidiary) suggests access to co-development, R&D, and supply chain synergies that can be leveraged to accelerate product iterations, reduce time-to-market, and gain competitive differentiation in sales pitches.

Market Momentum Awards and industry recognition for PET-CT innovation, along with a recent partnership with MedAxiom and a major product launch in 2025, position Positron as a credible innovator in cardiovascular and oncology imaging, supporting high-conviction selling to hospitals and imaging centers.

Sales Expansion A growing install base with new system deployments and a focus on North American healthcare providers creates recurring revenue opportunities through service contracts, maintenance, upgrades, and potential bundled offerings that align with cost-conscious, high-precision imaging needs.